New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Supercharging immunotherapy to stop breast cancer from spreading to the lung

Supercharging immunotherapy to stop breast cancer from spreading to the lung

byUniversity of GlasgowGraphical abstract. Credit:Journal of Experimental Medicine(2022). DOI: 10.1084/jem.20211431Breast cancer immunotherapy could be more effective if an immune ce
Oncology January 02,2024
Supercharging immunotherapy to stop breast cancer from spreading to the lung

Supercharging immunotherapy to stop breast cancer from spreading to the lung

byUniversity of GlasgowGraphical abstract. Credit:Journal of Experimental Medicine(2022). DOI: 10.1084/jem.20211431Breast cancer immunotherapy could be more effective if an immune ce
Oncology January 02,2024
Potential new series of drugs targeting cancer-driving protein BCL6

Potential new series of drugs targeting cancer-driving protein BCL6

byInstitute of Cancer ResearchThe BCL6 BTB domain dimer (in grey/green) and compound hits in pink, superimposed on each other in the main compound binding site. Credit: Dr Rob van Montfort lab /
Oncology January 02,2024
Potential new series of drugs targeting cancer-driving protein BCL6

Potential new series of drugs targeting cancer-driving protein BCL6

byInstitute of Cancer ResearchThe BCL6 BTB domain dimer (in grey/green) and compound hits in pink, superimposed on each other in the main compound binding site. Credit: Dr Rob van Montfort lab /
Oncology January 02,2024
Potential melanoma target bypasses therapeutic resistance to immune checkpoint blockers

Potential melanoma target bypasses therapeutic resistance to immune checkpoint blockers

by Jeff Hansen,University of Alabama at BirminghamConstitutive activation of JAK1/2 in IFNγR1KOmelanoma cells. a Identification of a JAK1/2-centric network of activated protein tyrosine ki
Oncology January 02,2024
Potential melanoma target bypasses therapeutic resistance to immune checkpoint blockers

Potential melanoma target bypasses therapeutic resistance to immune checkpoint blockers

by Jeff Hansen,University of Alabama at BirminghamConstitutive activation of JAK1/2 in IFNγR1KOmelanoma cells. a Identification of a JAK1/2-centric network of activated protein tyrosine ki
Oncology January 02,2024
Prostate tumor biology may be influenced by genetic ancestry

Prostate tumor biology may be influenced by genetic ancestry

byAmerican Association for Cancer ResearchSample collection sites and genetic admixture analysis. A, At clinical sites across Nigeria, 45 samples were collected. B, Admixture v1.3.0 was used to
Oncology January 02,2024
Prostate tumor biology may be influenced by genetic ancestry

Prostate tumor biology may be influenced by genetic ancestry

byAmerican Association for Cancer ResearchSample collection sites and genetic admixture analysis. A, At clinical sites across Nigeria, 45 samples were collected. B, Admixture v1.3.0 was used to
Oncology January 02,2024
Falling PSA levels found to predict longer survival in prostate cancer patients at high risk of metastases

Falling PSA levels found to predict longer survival in prostate cancer patients at high risk of metastases

byWolters Kluwer HealthTwelve-month landmark analysis of overall survival (OS) by prostate-specific antigen (PSA) decline subgroup for enzalutamide-treated men. Data cutoff: October 15, 2019. Cr
Oncology January 02,2024
Falling PSA levels found to predict longer survival in prostate cancer patients at high risk of metastases

Falling PSA levels found to predict longer survival in prostate cancer patients at high risk of metastases

byWolters Kluwer HealthTwelve-month landmark analysis of overall survival (OS) by prostate-specific antigen (PSA) decline subgroup for enzalutamide-treated men. Data cutoff: October 15, 2019. Cr
Oncology January 02,2024
Genetic testing for prostate cancer increases after introduction of point-of-care program

Genetic testing for prostate cancer increases after introduction of point-of-care program

byWolters Kluwer HealthCredit: Unsplash/CC0 Public DomainSome patients with prostate cancer have genetic mutations that may impact their treatment. A comprehensive, on-site genetic testing progr
Oncology January 02,2024
Genetic testing for prostate cancer increases after introduction of point-of-care program

Genetic testing for prostate cancer increases after introduction of point-of-care program

byWolters Kluwer HealthCredit: Unsplash/CC0 Public DomainSome patients with prostate cancer have genetic mutations that may impact their treatment. A comprehensive, on-site genetic testing progr
Oncology January 02,2024
Molecular mechanisms regulating prostate cancer hypoxia identified

Molecular mechanisms regulating prostate cancer hypoxia identified

by Melissa Rohman,Northwestern UniversityMicrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia,CC BY-SA 3.0A Northwestern Medicine
Oncology January 02,2024
Molecular mechanisms regulating prostate cancer hypoxia identified

Molecular mechanisms regulating prostate cancer hypoxia identified

by Melissa Rohman,Northwestern UniversityMicrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia,CC BY-SA 3.0A Northwestern Medicine
Oncology January 02,2024
Prostate cancer test: Is it time to ditch the digital rectal examination?

Prostate cancer test: Is it time to ditch the digital rectal examination?

by Stephen Hughes,The ConversationA man having his prostate gland examined. Credit: National Cancer Institute/WikimediaThe finger-up-the-bottom examination for prostate cancer has been drawn int
Oncology January 02,2024
Prostate cancer test: Is it time to ditch the digital rectal examination?

Prostate cancer test: Is it time to ditch the digital rectal examination?

by Stephen Hughes,The ConversationA man having his prostate gland examined. Credit: National Cancer Institute/WikimediaThe finger-up-the-bottom examination for prostate cancer has been drawn int
Oncology January 02,2024
New treatment approach for prostate cancer could stop resistance in its tracks

New treatment approach for prostate cancer could stop resistance in its tracks

bySanford Burnham Prebys Medical Discovery InstituteProstate cancer cells. Credit: NIH Image GalleryFor the first time, researchers have discovered that prostate cancer can be killed by targetin
Oncology January 02,2024
New treatment approach for prostate cancer could stop resistance in its tracks

New treatment approach for prostate cancer could stop resistance in its tracks

bySanford Burnham Prebys Medical Discovery InstituteProstate cancer cells. Credit: NIH Image GalleryFor the first time, researchers have discovered that prostate cancer can be killed by targetin
Oncology January 02,2024
Prostate cancer: Getting ever closer to diagnosis using an 'electronic nose'

Prostate cancer: Getting ever closer to diagnosis using an 'electronic nose'

by Politecnico di MilanoPrototype of an electronic nose developed by the Politecnico di Milano in partnership with Humanitas, capable of diagnosing a tumor using a urine sample with 82% accuracy. Cred
Oncology January 02,2024
Prostate cancer: Getting ever closer to diagnosis using an 'electronic nose'

Prostate cancer: Getting ever closer to diagnosis using an 'electronic nose'

by Politecnico di MilanoPrototype of an electronic nose developed by the Politecnico di Milano in partnership with Humanitas, capable of diagnosing a tumor using a urine sample with 82% accuracy. Cred
Oncology January 02,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com